全文获取类型
收费全文 | 5150篇 |
免费 | 578篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 42篇 |
儿科学 | 155篇 |
妇产科学 | 146篇 |
基础医学 | 745篇 |
口腔科学 | 32篇 |
临床医学 | 533篇 |
内科学 | 1154篇 |
皮肤病学 | 157篇 |
神经病学 | 414篇 |
特种医学 | 363篇 |
外科学 | 632篇 |
综合类 | 62篇 |
一般理论 | 2篇 |
预防医学 | 395篇 |
眼科学 | 60篇 |
药学 | 176篇 |
肿瘤学 | 668篇 |
出版年
2022年 | 36篇 |
2021年 | 93篇 |
2020年 | 50篇 |
2019年 | 89篇 |
2018年 | 68篇 |
2017年 | 88篇 |
2016年 | 76篇 |
2015年 | 102篇 |
2014年 | 148篇 |
2013年 | 160篇 |
2012年 | 234篇 |
2011年 | 236篇 |
2010年 | 151篇 |
2009年 | 138篇 |
2008年 | 190篇 |
2007年 | 217篇 |
2006年 | 226篇 |
2005年 | 214篇 |
2004年 | 240篇 |
2003年 | 222篇 |
2002年 | 200篇 |
2001年 | 203篇 |
2000年 | 206篇 |
1999年 | 166篇 |
1998年 | 102篇 |
1997年 | 80篇 |
1996年 | 78篇 |
1995年 | 61篇 |
1994年 | 62篇 |
1993年 | 60篇 |
1992年 | 118篇 |
1991年 | 115篇 |
1990年 | 97篇 |
1989年 | 115篇 |
1988年 | 114篇 |
1987年 | 102篇 |
1986年 | 116篇 |
1985年 | 86篇 |
1984年 | 67篇 |
1983年 | 68篇 |
1982年 | 53篇 |
1981年 | 33篇 |
1980年 | 32篇 |
1979年 | 47篇 |
1978年 | 41篇 |
1976年 | 33篇 |
1975年 | 38篇 |
1974年 | 33篇 |
1973年 | 25篇 |
1971年 | 24篇 |
排序方式: 共有5736条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
PC Chamyal A Mehta SL Ojha JR Bhardwaj 《Indian journal of otolaryngology and head and neck surgery》1991,43(1):26-27
Primary tuberculous pathology in nasolpolypi is a rare condition. A case of bilateral ethmoidal polypi with tubercular lesion diagnosed on histopathologlcal examination is being reported and the available relevant literature has been reviewed. 相似文献
7.
Sabrina Hundt Ulrike Haug Hermann Brenner 《Cancer epidemiology, biomarkers & prevention》2007,16(10):1935-1953
BACKGROUND: Despite different available methods for colorectal cancer (CRC) screening and their proven benefits, morbidity, and mortality of this malignancy are still high, partly due to low compliance with screening. Minimally invasive tests based on the analysis of blood specimens may overcome this problem. The purpose of this review was to give an overview of published studies on blood markers aimed at the early detection of CRC and to summarize their performance characteristics. METHOD: The PUBMED database was searched for relevant studies published until June 2006. Only studies with more than 20 cases and more than 20 controls were included. Information on the markers under study, on the underlying study populations, and on performance characteristics was extracted. Special attention was given to performance characteristics by tumor stage. RESULTS: Overall, 93 studies evaluating 70 different markers were included. Most studies were done on protein markers, but DNA markers and RNA markers were also investigated. Performance characteristics varied widely between different markers, but also between different studies using the same marker. Promising results were reported for some novel assays, e.g., assays based on SELDI-TOF MS or MALDI-TOF MS, for some proteins (e.g., soluble CD26 and bone sialoprotein) and also for some genetic assays (e.g., L6 mRNA), but evidence thus far is restricted to single studies with limited sample size and without further external validation. CONCLUSIONS: Larger prospective studies using study populations representing a screening population are needed to verify promising results. In addition, future studies should pay increased attention to the potential of detecting precursor lesions. 相似文献
8.
In an era of ongoing improvement in cancer patient survival, available long-term survival figures from cancer registries are often outdated and too pessimistic for two reasons: first, delay in availability of cancer registry data, typically in the order of a few years, and, second, application of cohort-based methods of survival analysis, which provide survival estimates for patients diagnosed many years ago. We developed a model-based period analysis approach aimed to overcome both problems. We provide extensive empirical evaluation of our approach by comparing its performance with that of previously available methods for monitoring of 5- and 10-year relative survival, with the use of data from the nationwide Finnish Cancer Registry of 490,279 patients ages >/=15 years and diagnosed with one of 20 common forms of cancer between 1953 and 1997. We show that, in most cases, the model-based approach predicts 5- and 10-year relative survival expectations of newly diagnosed patients quite closely and much better than any of the previously available methods, including standard period analysis. We conclude that the model-based approach may enable deriving up-to-date cancer survival rates even with the common latency in availability of cancer registry data. 相似文献
9.
A case of successful en bloc transplantation of a horseshoe kidney into a single recipient is reported. The literature is briefly reviewed. The use of horseshoe kidneys in transplantation is recommended in selected cases. 相似文献
10.
M R Howard J M Hows S M Gore J Barrett M K Brenner J M Goldman E C Gordon-Smith C Poynton H G Prentice J A Whittaker 《Transplantation》1990,49(3):547-553
Retrospectively we analyzed the histocompatibility data and clinical results of bone marrow transplantation in 51 patients who received marrow from unrelated donors (UD) from 1977 to 1987 at one of four UK BMT centers. We compared the results with those obtained in 51 transplants carried out at the same centers using HLA-identical (ID) sibling donors. Of the UD/recipient pairs 32 (63%) were serologically identical for HLA A, B, and DR antigens, and 37% showed varying degrees of mismatch. UD-BMT primary diagnoses were: severe aplastic anemia or Fanconi's anemia (n = 17), acute leukemia (n = 11), chronic myeloid leukemia (n = 21), and other conditions (n = 2). T cell depletion of the graft was associated with a significant improvement in survival in both UD and ID-BMT. Graft failure was more common in recipients of UD than of ID transplants (13 [25%] vs. 5 [10%] P = 0.05) but there was no significant difference in the frequency of acute or chronic graft-versus-host disease. Actuarial survival was superior for recipients of ID transplants (UD vs. ID: 49% vs. 78%, respectively, at 3 months; 32% vs. 63% at one year). Reduced survival for recipients of UD-BMT was confirmed in case control regression analysis (relative risk 3.0, P = 0.01). Nevertheless in patients whose only alternative is a partially mismatched family donor we think that UD-BMT is justified. 相似文献